Literature DB >> 18356810

Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies.

John A Eckman1, Robert G Hamilton, Laura M Gober, Patricia M Sterba, Sarbjit S Saini.   

Abstract

Potentially pathogenic IgG autoantibodies to IgE or its receptor, Fc epsilonRIalpha, have been detected in approximately 40% of chronic idiopathic urticaria (CIU) patients. CIU patients' basophils display distinct altered Fc epsilonRIalpha-mediated degranulation. CIU patients with basophil histamine release in response to polyclonal goat anti-human IgE > or = 10% are classified as CIU responders (CIU-R) and < 10% are CIU non-responders (CIU-NR). We compared the presence of autoantibodies to basophil degranulation phenotypes and to disease status (active or inactive). Sera were collected from non-CIU subjects and CIU subjects who participated in a longitudinal study of disease severity and had defined basophil degranulation phenotypes. Immunoenzymetric assays (IEMA) quantified IgG anti-Fc epsilonRIalpha and anti-IgE. IgG anti-Fc epsilonRIalpha antibody was detected in 57% of CIU-R (n=35), 55% of CIU-NR (n=29), and 57% of non-CIU subjects (n=23), whereas IgG anti-IgE was present in 43% of CIU-R, 45% of CIU-NR, and 30% of non-CIU subjects. Both the autoantibody levels and the functional basophil phenotype remained stable in subjects with active disease (n=16), whereas there was an enhancement in basophil function as subjects evolved into a state of remission (n=6), which appears independent of the presence of autoantibody. IEMAs detected a similar frequency of autoantibodies in CIU-R, CIU-NR, and non-CIU subjects. Basophil function may be independent of IEMA-detected autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356810     DOI: 10.1038/jid.2008.55

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  44 in total

Review 1.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 2.  The urticarias: pathophysiology and management.

Authors:  Clive Grattan
Journal:  Clin Med (Lond)       Date:  2012-04       Impact factor: 2.659

3.  Association of basophil parameters with disease severity and duration in chronic spontaneous urticaria (CSU).

Authors:  Amy H Huang; Kristin L Chichester; Sarbjit S Saini
Journal:  J Allergy Clin Immunol Pract       Date:  2019-08-14

4.  Autoantibodies to IgE and FcεRI and the natural variability of spleen tyrosine kinase expression in basophils.

Authors:  Donald MacGlashan
Journal:  J Allergy Clin Immunol       Date:  2018-06-01       Impact factor: 10.793

Review 5.  IgE-dependent signaling as a therapeutic target for allergies.

Authors:  Donald W MacGlashan
Journal:  Trends Pharmacol Sci       Date:  2012-06-30       Impact factor: 14.819

6.  Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria.

Authors:  Priyal Amin; Linda Levin; Sarah J Holmes; Jillian Picard; Jonathan A Bernstein
Journal:  J Allergy Clin Immunol Pract       Date:  2015-02-11

7.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.

Authors:  Thamiris Palacios; Leland Stillman; Larry Borish; Monica Lawrence
Journal:  J Allergy Clin Immunol Pract       Date:  2015-12-24

Review 9.  Chronic Spontaneous Urticaria: The Devil's Itch.

Authors:  Sarbjit S Saini; Allen P Kaplan
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jul - Aug

10.  Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils.

Authors:  Susan S Ishmael; Donald W MacGlashan
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.